Molecular markers in prostate cancer. Part I: Predicting lethality

Asian Journal of Andrology

Volumn 11, Issue 1, 2009, Pages 14-21

  Agrawal, Sachin ^a   Dunsmuir, William D ^a  

^a ST PETER S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN RECEPTOR; BETA MICROSEMINOPROTEIN; BRCA2 PROTEIN; CHORIONIC GONADOTROPIN ALPHA SUBUNIT; CYCLIN D1; EARLY PROSTATE CELL ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; GENOMIC DNA; GLUTATHIONE TRANSFERASE P1; INTERLEUKIN 6; KALLIKREIN; NEURON SPECIFIC ENOLASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P27; PROTEIN P53; RIBONUCLEASE L; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UROKINASE; UVOMORULIN; PROSTATE CANCER ANTIGEN 3, HUMAN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

CANCER RISK; CELL RENEWAL; DISEASE MARKER; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTOXICITY; HUMAN; HYPOXIA; LETHALITY; PROSTATE CANCER; PROSTATE STEM CELL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATITIS; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; STEM CELL; BLOOD; GENETICS; MALE; METABOLISM; MORTALITY; PREDICTION AND FORECASTING; PROGNOSIS; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY; URINE;

ANTIGENS, NEOPLASM; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 69449099090     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2008.20     Document Type: Review

References (72)

1. Parker C. Active surveillance: Towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004; 5: 101-6.
2. Lawson DA, Witte ON. Stem cells in prostate cancer initiation and progression. J Clin Invest 2007; 117: 2044-50.
3. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209-21.
4. Hällström TM, Laiho M. Genetic changes and DNA damage responses in the prostate. Prostate 2008; 68: 902-18.
5. Vaughn DJ, Brown AW Jr, Harker WG, Huh S, Miller L, et al. Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma. Cancer 2004; 100: 746-50.
6. Ramírez ML, Nelson EC, Evans CP. Beyond prostate-specific antigen: alternate serum markers. Prostate Cancer Prostatic Dis 2008; 11: 216-29.
7. Rogers CG, Yan G, Zha S, Gonzalgo ML, Isaacs WB, et al. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme, a racemase protein. J Urol 2004; 172: 1501-3.
8. Dunsmuir WD, Gillett CE, Meyer LC, Young MP, Corbishley C, et al. Molecular markers for predicting prostate cancer stage and survival. BJU Int 2000; 86: 869-78.
9. Culig Z, Klocker H, Bartsch G, Hobisch A. Androgen receptor mutations in carcinoma of the prostate: Significance for endocrine therapy. Am J Pharmacogenom 2001; 1: 241-9.
10. Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, et al Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 2007; 6: 51-60.
11. Hussain A, Dawson NA. Chemotherapy in hormone resistant prostate cancer. In: Basow DS, editor. UpToDate Waltham, MA: UpToDate; 2008.
12. Moon C, Park JC, Chae YK, Yun JH, Kim S. Current status of experimental therapeutics for prostate cancer. Cancer Lett 2008; 266: 116-34.
13. Walczak JR, Pili R, Carducci MA. Novel and emerging treatment techniques in prostate cancer. In: Basow DS, editor. Up- ToDate. Waltham, MA: UpToDate; 2008.
14. Edwards SM, Eeles RA. Unravelling the genetics of prostate cancer. Am J Med Genet C Semin Med Genet 2004; 129C: 65-73.
15. De Miguel P, Royuela M, Bethencourt R, Ruiz A, Fraile B, et al. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. Cytokine 1999; 11: 722-7.
16. Golias Ch, Charalabopoulos A, Stagikas D, Giannakopoulos X, Peschos D, et al. Molecular profiling and genomic microarrays in prostate cancer. Exp Oncol 2007; 29: 82-4.
17. Bose SK, Bullard RS, Donald CD, Oncogenic role of Engrailed-2 (En-2) in prostate cancer cell growth and survival. Translat Oncogenom 2008; 2: 37-43.
18. Gibson W, Green A, Bullard RS, Eaddy AC, Donald CD. Inhibition of PAX2 expression results in alternate cell death pathways in prostate cancer cells differing in p53 status. Cancer Lett 2007; 248: 251-61.
19. Kasper S. Stem cells: The root of prostate cancer? J Cell Physiol 2008; 216: 332-6.
20. Maitland NJ, Collins AT. Prostate cancer stem cells: A new target for therapy. J Clin Oncol 2008; 26: 2862-70.
21. Schiffer E. Biomarkers for prostate cancer. World J Urol 2007; 25: 557-62.
22. Harden SV, Guo Z, Epstein JI, Sidransky D. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol 2003; 169: 1138-42.
23. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001; 159: 2159-65.
24. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, et al. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003; 9: 370-6.
25. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, et al. UK Genetic Prostate Cancer Study Collaborators; British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, et al. editors. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40: 316-21.
26. Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol 2000; 163: 311-6.
27. Reeves JR, Dulude H, Panchal C, Daigneault L, Ramnani DM. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin Cancer Res 2006; 12: 6018-22.
28. Vecchione A, Gottardo F, Gomella LG, Wildemore B, Fassan M, et al. Molecular genetics of prostate cancer: Clinical translational opportunities. J Exp Clin Cancer Res 2007; 26: 25-37.
29. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000; 60: 6111-5.
30. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978; 15: 340-5.
31. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999; 155: 1985-92.
32. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, et al. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-9.
33. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, et al. DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-16.
34. Gen-Probe Incorporated data on file. 2007. Available at http://www.pca3.org/pro/pca3-utility.
35. Haese A, Van Poppel H, Marberger M, Mulders P, Abbou CC, et al. The value of the PCA3 assay in guiding decision which men with a negative prostate biopsy need immediate repeat biopsy: Preliminary European data. Eur Urol 2007; 6 (Suppl): 48 (Abstract 101).
36. Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008; 180: 1975-8; discussion 1978-9.
37. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7: 927-35.
38. Hara N, Kasahara T, Kawasaki T, Bilim V, Obara K, et al. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen and prostate stem cell antigen in one milliliter of peripheral blood: Value for the staging of prostate cancer. Clin Cancer Res 2002; 8: 1794-9.
39. Isaacs W, De Marzo A, Nelson WG. Focus on prostate cancer. Cancer Cell 2002; 2: 113-6.
40. Bauer JJ, Sesterhenn IA, Mostofi KF, McLeod DG, Srivastava S, et al p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1995; 1: 1295-300.
41. Malins DC, Johnson PM, Barker EA, Polissar NL, Wheeler TM, et al. Cancer-related changes in prostate DNA as men age and early identification of metastasis in primary prostate tumors. Proc Natl Acad Sci USA 2003; 100: 5401-6.
42. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002; 30: 181-4.
43. Wagenlehner FM, Elkahwaji JE, Algaba F, Bjerklund-Johansen T, Naber KG, et al. The role of inflammation and infection in the pathogenesis of prostate carcinoma. BJU Int 2007; 100: 733-7.
44. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002; 32: 581-3.
45. Salm SN, Burger PE, Coetzee S, Goto K, Moscatelli D, et al. TGF-{beta} maintains dormancy of prostatic stem cells in the proximal region of ducts. J Cell Biol 2005; 170: 81-90.
46. Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006; 8: 826-32.
47. Jhavar SG, Fisher C, Jackson A, Reinsberg SA, Dennis N, et al. Processing of radical prostatectomy specimens for correlation of data from histopathological, molecular biological and radiological studies: A new whole organ technique. J Clin Pathol 2005; 58: 504-8.
48. Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 2005; 23: 6569-75.
49. Eeles RA. Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Dis 1999; 2: 9-15.
50. Ostrander EA, Johannesson B. Prostate cancer susceptibility loci: finding the genes. Adv Exp Med Biol 2008; 617: 179-90.
51. Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, et al. A novel founder mutation in the RNASEL gene, 471de-lAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 2002; 71: 981-4.
52. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990; 17: 337-47.
53. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, et al Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 1995; 55: 2959-62
54. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2006; 2: E25.
55. Kommu S, Sharifi R, Eeles RA. The proteomic approach to urological biomarkers. BJU Int 2004; 94: 1215-6.
56. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 1576-8.
57. Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate-specific antigen levels between 2.5 and 15.0 ng/mL. J Urol 2004; 172: 1302-5.
58. Girinsky T, Koumenis C, Graeber TG, Peehl DM, Giaccia AJ. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res 1995; 55: 3726-31.
59. Kiviharju-af Hällström TM, Jäämaa S, Mönkkönen M, Peltonen K, Andersson LC, et al. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci USA 2007; 104: 7211-6.
60. Chan N, Milosevic M, Bristow RG. Tumor hypoxia, DNA repair and prostate cancer progression: New targets and new therapies. Future Oncol 2007; 3: 329-41.
61. De Marzo AM, Putzi MJ, Nelson WG. New concepts in the pathology of prostatic epithelial carcinogenesis. Urology 2001; 57: 103-14.
62. Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA. Postatrophic hyperplasia of the prostate gland: Neoplastic precursor or innocent bystander? Am J Pathol 2001; 158: 1767-73.
63. Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ. Prostatitis as a risk factor for prostate cancer. Epidemiology 2004; 15: 93-9.
64. Krieger JN, Riley DE, Vesella RL, Miner DC, Ross SO, et al. Bacterial dna sequences in prostate tissue from patients with prostate cancer and chronic prostatitis. J Urol 2000; 164: 1221-8.
65. Adhami VM, Malik A, Zaman N, Sarfaraz S, Siddiqui IA, et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2007; 13: 1611-9.
66. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961; 14: 213-22.
67. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.
68. Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA. 2002; 99: 16220-5.
69. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51.
70. Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, et al Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res 2006; 66: 8598-607.
71. Masters JR, Kane C, Yamamoto H, Ahmed A. Prostate cancer stem cell therapy: Hype or hope? Prostate Cancer Prostatic Dis 22 April 2008 [Epub ahead of print].
72. Figueiredo ML, Kao C, Wu L. Advances in preclinical investigation of prostate cancer gene therapy. Mol Ther 2007; 15: 1053-64.